Glycanostics Company Profile

Background

Overview

Glycanostics is an innovative biotechnology start-up established in 2017, dedicated to revolutionizing cancer diagnostics through early-stage, highly accurate, and unique tests. The company specializes in developing diagnostic assays that detect glycan changes in blood serum, offering a non-invasive and affordable approach to cancer detection. Founded by internationally recognized scientists Ján Tkáč and Tomáš Bertók, Glycanostics aims to address the challenges in early cancer detection by providing reliable and accessible diagnostic solutions.

Mission and Vision

Mission: To develop diagnostic tests utilizing unique glycan-based technology to detect 11 types of cancer in their early stages with high accuracy.

Vision: To create a world where cancer is diagnosed early and treated successfully.

Industry Significance

Glycanostics operates within the biotechnology and healthcare sectors, focusing on the critical area of early cancer detection. By leveraging glycan analysis, the company aims to enhance diagnostic precision, reduce unnecessary procedures, and improve patient outcomes, thereby contributing significantly to the advancement of personalized medicine and public health.

Key Strategic Focus

Core Objectives

Develop and commercialize non-invasive diagnostic tests for early-stage cancer detection.

Expand the diagnostic portfolio to cover multiple cancer types beyond the initial focus on prostate cancer.

Establish strategic partnerships with multinational pharmaceutical and diagnostic companies to facilitate global market penetration.

Areas of Specialization

Glycan-based diagnostics: Utilizing changes in glycan structures on glycoprotein biomarkers to detect cancer.

Non-invasive liquid biopsy methods: Analyzing blood serum to identify early cancer markers.

Key Technologies Utilized

Magnetic-based Enzyme-Linked Immunosorbent Assay (ELISA): A proprietary technology for detecting glycan changes in blood serum.

Primary Markets Targeted

European Union and United States: Focusing on markets with advanced healthcare infrastructures and high demand for innovative diagnostic solutions.

Financials and Funding

Funding History

European Innovation Council (EIC) Accelerator Grant: In 2021, Glycanostics secured nearly €2 million from the EIC Accelerator, marking a significant milestone in the company's funding journey.

Crowdberry Investment: In September 2021, the company received €1 million in investment from a syndicate of investors on the Crowdberry platform and the CB Growth ONE investment fund.

Utilization of Capital

The funds have been allocated towards completing the development of diagnostic tests, conducting clinical validations, patenting biomarkers, and preparing for CE registration, which is essential for commercialization in the European market.

Pipeline Development

Key Pipeline Candidates

Prostate Cancer Diagnostic Test: Currently in the pre-clinical validation stage, demonstrating over 95% accuracy, with plans for CE certification in 2022.

Breast Cancer Diagnostic Test: Scheduled for development and market introduction in 2023.

Target Conditions

Prostate cancer

Breast cancer

Lung cancer

Pancreatic cancer

Colorectal cancer

Stomach cancer

Liver cancer

Ovarian cancer

Testicular cancer

Bladder cancer

Thyroid cancer

Anticipated Milestones

2022: CE certification for the prostate cancer diagnostic test.

2023: Introduction of the breast cancer diagnostic test.

2024 and Beyond: Development and commercialization of diagnostic tests for additional cancer types.

Technological Platform and Innovation

Proprietary Technologies

Magnetic-based ELISA: A patented technology that enables the detection of glycan changes in blood serum, facilitating early cancer detection.

Significant Scientific Methods

Glycan Analysis: Employing advanced techniques to analyze glycan structures on glycoproteins, providing insights into disease presence and progression.

Liquid Biopsy: Utilizing blood serum samples to detect cancer markers, offering a non-invasive alternative to traditional biopsy methods.

Leadership Team

Executive Profiles

Eva Kováčová: Chief Executive Officer (CEO)

Professional Background: Over 18 years of experience in international pharmaceutical mergers, acquisitions, and licensing processes, primarily with GlaxoSmithKline.

Key Contributions: Joined Glycanostics in 2021, bringing strategic leadership to drive the company's growth and market expansion.

Ján Tkáč: Chief Scientific Officer (CSO)

Professional Background: Renowned scientist with expertise in glycan analysis and cancer diagnostics, holding a D.Sc. and Ph.D.

Key Contributions: Co-founder of Glycanostics, leading the scientific direction and development of diagnostic technologies.

Tomáš Bertók: Chief Technology Officer (CTO)

Professional Background: Scientist with a focus on glycan-based diagnostics, holding a Ph.D.

Key Contributions: Co-founder of Glycanostics, responsible for technological innovation and product development.

Competitor Profile

Market Insights and Dynamics

The global cancer diagnostics market is experiencing significant growth, driven by the increasing prevalence of cancer and the demand for early detection methods. Innovations in non-invasive diagnostic technologies, such as liquid biopsies and glycan-based assays, are gaining traction, presenting opportunities for companies like Glycanostics to capture market share.

Competitor Analysis

MultiplexDX: A Slovak biotech company specializing in multiplex diagnostics, focusing on early detection of infectious diseases.

Sensoneo: A Slovak company providing smart waste management solutions, operating in a different sector but representing local innovation.

Strategic Collaborations and Partnerships

Glycanostics is actively seeking collaborations with clinical laboratories and hospitals to obtain serum samples for clinical validations and with clinicians/oncologists to address clinical needs.

Operational Insights

Glycanostics differentiates itself through its proprietary glycan-based diagnostic technology, offering a non-invasive, accurate, and affordable solution for early cancer detection. The company's focus on multiple cancer types and its commitment to global market expansion position it favorably in the competitive landscape.

Strategic Opportunities and Future Directions

Strategic Roadmap

Short-Term Goals: Achieve CE certification for the prostate cancer diagnostic test, initiate commercialization in Europe, and expand the product portfolio.

Long-Term Goals: Obtain FDA approval for the U.S. market, establish global partnerships, and scale operations to meet international demand.

Opportunities for Expansion

Leveraging the glycan-based diagnostic platform to develop tests for additional cancer types.

Exploring partnerships with pharmaceutical companies for co-development and distribution.

Entering emerging markets with high unmet needs in cancer diagnostics.

Positioning for Future Objectives

Glycanostics' innovative technology, strong leadership team, and strategic funding position the company to achieve its objectives, enhance patient care, and contribute to the advancement of cancer diagnostics globally.